However, in the Myeloma XI study, and a small study reporting only as recruitment to Myeloma XI13 concluded, significant toxicity was seen with HDAC inhibition and was associated with compromised delivery of the lenalidomide‐vorinostat combination. The gene discussed is HDAC9; the disease is plasma cell myeloma.